ZymoGenetics Furthers Bristol's "Multi-Pronged" Approach To HCV, Sigal Says
This article was originally published in The Pink Sheet Daily
Executive Summary
R&D President Sigal talks about how the acquisition of ZymoGenetics fits into Bristol's research strategy in his first public comments to investors since March.